Therapeuticsmd, Inc. · NASDAQ:TXMD
Therapeuticsmd — 2019 Cantor Healthcare Conference
25 slides from Therapeuticsmd's conference presentation, October 2019
Slide 1: Investor Presentation: Building a Premier Women's Health Portfolio
Investor Presentation October 2019 Building a Premier Women’s Health Portfolio 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as “we” and “our”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than
Slide 3: IMVEXXY
¥ Imvexxy IMVEXXY estradiol vaginal inserts) 4 mcg: 10 mcg TherapeuticsMD For Her: For Life. 3
Slide 4: Launch Results Remain Strong and On-Track: Strategy is Working
Launch Results Remain Strong and On-Track: Strategy is Working Imvexxy TRx Launch Comparison 70,000 60,000 9% 8% 47,900 50,000 43,200 6% 44,600 40,000 4% 37,500 28,700 30,000 2% 21,000 28,100 20,000 19,800 8,800 10,000 8,400 0 Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 M
Slide 5: Continued Strong Patient Adherence
Continued Strong Patient Adherence IMVEXXY Patient Adherence1,2 Maximum Average # Fills Month Initial Allowable Fills for Those Prescription Filled Given the Month Patients of Initial Fill Aug 2019 1 Fill 1 Fill IMVEXXY: 3.8 fills/yr3 (through Aug) Jul 2019 1.9 Fills 2 Fills • Vaginal creams: averag
Slide 6: Value of Additional Fills
Value of Additional Fills Percent of market based on patient count of 2.3M and 4 fills per year Average Net 4 Revenue / Unit 25% 35% 45% 55% Fills/year $80 $184M $257.6M $331.2M $404.8M $100 $230M $322M $414M $506M Percent of market based on patient Count of 2.3M and 5 fills per year Average Net Rev
Slide 7: The VVA Market Exceeds $1.7B Gross Revenue Annually
The VVA Market Exceeds $1.7B Gross Revenue Annually 12 Months through June Product Gross Dollars for 20181 2019 Total Units1 Estrace® Cream Brand & Generics 2,000,000 $554,450,000 Premarin® 1,190,000 $460,760,000 Vagifem® Brand & Generics 1,500,000 $454,550,000 Estring® 259,000 $114,360,000 Osphena®
Slide 8: Commercial Payer Status
Commercial Payer Status Top 10 Plans Account for ~71% of all Commercial Pharmacy Lives Plan % of Lives1 Status2 New CVS 15.4% Adjudicating as of September 2019 ESI 15.3% Adjudicating as of 10/1/18 United 7.5% Adjudicating as of 3/1/19 Anthem 7.3% Adjudicating as of August 2018 Prime 6.5% Adjudicatin
Slide 9: Medicare Part D Payer Status
Medicare Part D Payer Status Decisions Expected 3Q/4Q19 Top 6 Plans Account for ~78% of all Medicare Part D Pharmacy Lives Plan % of Lives1 Status2 United 20.7% Adjudicating as of 2/1/19 Humana 17.9% Decision expected 3Q/4Q19 CVS Caremark 14.1% Decision expected 3Q/4Q19 Wellcare with 13.6% Decision
Slide 10: BIJUVA
BiyUV ann BIJUVA (:stradiol and progesterone) capsules TherapeuticsMD’ For Her: For Life. 10
Slide 11: A Large Target Market For BIJUVA
A Large Target Market For BIJUVA No Q2 Launched April 17, 2019 Target FDA-approved separate Reps directed to focus on ~10 Q2 bio-identical Estrogen & prescribers in their territory until improved payer Progesterone pills segment coverage Image ~3.9M TRx (each)1 I $836M2 TAM BIJUVA introduced into Bi
Slide 12: August Launch Metrics
August Launch Metrics BIJUVA Launch Metrics Total paid scripts dispensed to patients1 (since launch through August 31, 2019) ~14,200 Total paid scripts (August 1-31, 2019) ~5,300 Total patients (since launch through August 31, 2019) ~6,800 Total prescribers2 (since launch through August 31, 2019) ~3
Slide 13: Commercial Payer Update
Commercial Payer Update Coverage Decisions Expected by 4Q19 Quicker Process to Top 10 Plans Account for ~71% Payer Coverage than IMVEXXY of all Commercial Pharmacy Lives § Commercial segment represents vast Plan % of Lives1 Status2 majority of BIJUVA patients § Expect 3-4 quarters coverage cycle (fr
Slide 14: Compounding Pharmacy Onboarding Process and Status
Compounding Pharmacy Onboarding Process and Status 124 In Vetting Process 80 Contracting 10,759 CBHRT HCP’s In Contracting 2,183 Process 124 National High Tier Targets Reach 105 Live Accounts Live Accounts 105 § Unique compounded bio-identical hormone replacement therapy (CBRT) prescribers Identifie
Slide 15: Market Opportunity
Market Opportunity Total Addressable FDA Market: 3.9M Total Addressable Compounding Market: 12M Percent of Addressable Market Average Net Revenue / Unit 25% 35% 45% 55% $80 $316M $442.4M $568.8M $695.2M $100 $395M $553M $711M $869M Market opportunity is calculated by multiplying the annual addressab
Slide 16: ANNOVERA
Annovera ANNOVERA ethiny Delive TherapeuticsMD’ For Ler: For Life. 16
Slide 17: U.S. Contraceptive Market
U.S. Contraceptive Market $5B U.S. net sales1 ~ 90M annual scripts to ~20M women2 Complete control but no long acting benefits No Long-acting benefits without a procedure offering complete control over fertility and menstruation Long-acting benefits but requires a procedure and does not offer comple
Slide 18: Commercial Payer Update
Commercial Payer Update Coverage Decisions Expected to be finalized 1Q20 Top 10 Plans Account for ~71% of all Commercial Pharmacy Lives Plan % of Lives1 Status2 CVS 15.4% In discussions New ESI 15.3% Adjudicating at T3 as of September 2019 United 7.5% In discussions New Anthem 7.3% Adjudicating at T
Slide 19: Commercial Payer Update: Selected Regional Plan Coverage
Commercial Payer Update Coverage Decisions Expected to be finalized 1Q20 Selected Regional Plan Coverage Plan % of Lives1 Status2 MC-Rx (ProcareRx) 0.64% Adjudicating as of April 2019 New Magellan Rx 0.47% Adjudicating at no copay as of August 2019 BCBS of 0.47% Adjudicating at no copay as of August
Slide 20: ANNOVERA Test and Learn Market Introduction Update
ANNOVERA Test and Learn Market Introduction Update § ANNOVERA Test and Learn Market Introduction has begun No § Full launch expected in 1Q 2020 § Current Test and Learn Market Introduction sales staffing § 36 Sales Representatives from existing 190 territories will now promote ANNOVERA in addition t
Slide 21: ANNOVERA Unique Commercial Payer Environment
ANNOVERA Unique Commercial Payer Environment § Commercial payer environment for contraceptives provides patient affordability without the need for a TXMD open access program § In 2012, the Affordable Care Act (ACA) required all health insurances to cover, without cost-sharing, the full range of cont
Slide 22: Birth Control State Laws Regardless of ACA Mandates
BIRTH CONTROL STATE LAWS REGARDLESS OF ACA MANDATES 11 STATES, plus Washington D.C., REQUIRE COVERAGE WITH NO COPAY REGARDLESS OF ACA DECISION (~51 Million women in these states) 2 New * ANNOVERA1 coverage required with no co-pay 1 ANNOVERA coverage required with co-pay 1 Data on file (July 2019). 2
Slide 23: Birth Control State Laws Regardless of ACA Mandates
BIRTH CONTROL STATE LAWS REGARDLESS OF ACA MANDATES 8 STATES REQUIRE COVERAGE WITH COPAY REGARDLESS OF ACA DECISION (~27 Million women in these states) 1 ANNOVERA coverage required with co-pay ANNOVERA1 coverage required with no co-pay 1 Data on file (July 2019). 23 23
Slide 24: Market Opportunity
Market Opportunity Addressable Birth Control Market Rx Options NRx: 28M Percent of Overall Birth Control Market NRx Average Net Revenue / Unit 1.0% 1.5% 2.0% 2.5% $1,000 $280M $420M $560M $700M $1,500 $420M $630M $840M $1.05B $1,750 $490M $735M $980M $1.2B Addressable NuvaRing Market NRx: 1.2M Perce
Slide 25: The Power of the Portfolio: Multiple Paths to $1B of Peak Sales
The Power of the Portfolio Multiple Paths to $1B of Peak Sales Percent of Market Based on Patient Count of 2.3M and 4 fills per year Average Net Revenue / Unit 25% 35% 45% 55% $80 $184M $257.6M $331.2M $404.8M $100 $230M $322M $414M $506M Total Addressable FDA Market : 3.8M Total Addressable Compoun